In primary prostate cancer, 14% of participating RadOncs “fully agreed” and 31% “agreed” on the routine use of diagnostic PSMA PET/CT, while 19% “disagreed” and 10% “strongly disagreed” with using diagnostic PSMA PET/CT ahead of radiotherapy (Q10; Fig. 2a). This evidence concerns the gene FOLH1 and Familial prostate cancer.